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n this article, we review the utilization of
endophenotypes in research into the genetics of schizo-
phrenia,focusing on neurophysiological measures.Since
Bleuler
1 coined the term “schizophrenia,”this complex
and devastating disorder has gone through significant iter-
ations in terms of how the scientific community concep-
tualizes it.When Bleuler utilized his impressive clinical
experience and intuition in describing schizophrenia,he
recognized that schizophrenia represents a group of dis-
orders that share important unifying underlying features.
Initially, psychological developmental factors such as
aberrant communication styles
2,3 were felt to cause schiz-
ophrenia.Then,the seminal Danish studies of Kety et al
4
revealed the clear genetic transmission of schizophrenia
and schizotypy-related abnormalities of psychological
functioning subsumed under the term “schizotaxa.”
5The
seminal contributions of these and other family studies
pointed the way for the current conceptualization of
schizophrenia as one of the wide-ranging group of com-
plex genetic disorders (Figure 1).Unlike the mendelian-
dominant heritability pattern of Huntington’s disease,
schizophrenia may represent a group of related disorders
with substantial heterogeneity.
6
Schizophrenia has undergone a transition from being
viewed as a psychologically caused familial disorder to
being understood as a complex genetic disorder in which
multiple genes contribute in an additive or perhaps inter-
active,oligogenic fashion to yield a total risk or a vulner-
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Specifying the complex genetic architecture of the “fuzzy”
clinical phenotype of schizophrenia is an imposing prob-
lem. Utilizing metabolic, neurocognitive, and neurophys-
iological “intermediate” endophenotypic measures offers
significant advantages from a statistical genetics stand-
point. Endophenotypic measures are amenable to quan-
titative genetic analyses, conferring upon them a major
methodological advantage compared with largely quali-
tative diagnoses using the Diagnostic and Statistical
Manual of Mental Health, 4th Edition (DSM-IV).
Endophenotypic deficits occur across the schizophrenia
spectrum in schizophrenia patients, schizotypal patients,
and clinically unaffected relatives of schizophrenia
patients. Neurophysiological measures, such as P50 event-
related suppression and the prepulse inhibition (PPI) of
the startle response, are endophenotypes that can be con-
ceptualized as being impaired because of a single genetic
abnormality in the functional cascade of DNA to RNA to
protein. The “endophenotype approach” is also being
used to understand other medical disorders, such as colon
cancer, hemochromatosis, and hypertension, where there
is interplay between genetically conferred vulnerability
and nongenetic stressors. The power and utility of utiliz-
ing endophenotypes to understand the genetics of schiz-
ophrenia is discussed in detail in this article.  
© 2005, LLS SAS Dialogues Clin Neurosci. 2005;7:125-135.ability to developing the disorder.Interestingly,in a sort
of figure ground reversal,the initial enthusiasm of seeing
schizophrenia as an easy-to-dissect genetic disorder was
eventually replaced by the understanding that schizo-
phrenia is about 50% genetically mediated
7 with the
remainder of disease liability probably attributable to
nongenetic factors.
8-10
The evolution of our understanding of schizophrenia as a
family of disorders that are mediated by complex genetic
vulnerability and gene–environment interactions parallel
the advances seen in the conceptualization of many other
medical disorders,such as colon cancer,hemochromato-
sis,diabetes,and hypertension.
7 Interestingly,all of these
disorders are felt to be attributable to a complex interplay
of vulnerability genes that predispose an individual to
developing a disease and nongenetic “second hits”that
precipitate the disorders (Figure 2).If the genetic loading
or risk is strong enough (for example,as in multiplex fam-
ilies),even minor precipitants may result in the develop-
ment of the disorder.On the other hand,if the cumulative
genetic risk of developing schizophrenia is relatively mild,
it may take a more profound nongenetic second hit
(Figure 2) to start the cascade of events that ultimately
result in the full expression of the disease.
There is an interesting “natural history” in the schizo-
phrenia literature itself.First,there were descriptions of
the disorder and associated “deficits”in many domains.
Second,studies of clinically unaffected relatives of schiz-
ophrenia patients pointed the way to an intermediate
state of impairment (called endophenotypes) in each of
these independently studied domains. These types of
deficits occur across multiple domains such as metabolic
functioning (catechol-O-methyltransferase [COMT]),
neurophysiology (P50 event-related potential [ERP] sup-
pression),and neurocognition (vigilance,as measured by
the continuous performance task [CPT],and verbal mem-
ory,as measured by the California Verbal Learning Test
[CVLT]).
7The “intermediate”or partial deficits found in
clinically unaffected relatives of schizophrenia patients
gave investigators the insight crucial for the development
and understanding of “endophenotypes”or intermediate
phenotypes.Whereas the “fuzzy” clinical phenotype of
schizophrenia is quite difficult to characterize,laboratory-
based endophenotypes may be more closely linked to
specific genetic abnormalities that are partially or wholly
Basic research
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Selected abbreviations and acronyms
COMT catechol-O-methyltransferase
CSPT cortico-striato-pallido-thalamic (circuitry)
ERP event-related potential
PPI prepulse inhibition
SNP single nucleotide polymorphism
Figure 1. Genetic architecture of complex disorders. This illustrates a major conundrum of research into complex human disorders. The Huntington’s
gene was identified 20 years ago, but has not yet led to a genetic “cure.” The profoundly important potential of genetic treatments for even
more “complex genetic disorders” (eg, schizophrenia, hypertension, and diabetes) will depend on related scientific advances.
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*expressed (ie,variable penetrance) in clinically unaffected
relatives of schizophrenia patients.This variable expres-
sion makes these endophenotypes amenable to statistical
approaches utilizing quantitative trait methodologies.
11-14
Thus, the picture that was painted is that for many of
these endophenotypes,there are:(i) findings of deficits in
schizophrenia patients versus normal comparison sub-
jects;and (ii) the deficits are identified across the schizo-
phrenia spectrum (including schizotypal personality dis-
ordered patients and clinically unaffected family members
of schizophrenia patients) (Table I).
15-47 In addition,across
the schizophrenia spectrum,it is observed that increasing
deficits in these endophenotypes are noted with increas-
ing genetic load or genetic risk.For example,groups of
first-degree relatives of schizophrenia patients typically
have a greater level of endophenotypic abnormality than
groups of second-degree relatives,etc.Thus,there is the
explicit assumption that “levels”of genetic relative risk
48
act as powerful predisposing factors that make the indi-
vidual vulnerable to developing schizophrenia (Figure 2).
In parallel,as the power of “strong inference”
49 in molec-
ular biology became apparent,the understanding of the
template of “DNA to RNA to protein” became very
important across all species.In concert with these findings,
the human genome project has identified the sequence of
basepairs that characterize the human genome.The chal-
lenge for understanding the basis of mendelian-dominant
genetic disorders (eg,Huntington’s disease) and the many
“partially”genetic disorders (eg,hypertension,diabetes,
bipolar disorder,Tourette syndrome,and schizophrenia;
Figure 1) is to parse the clinical heterogeneity and com-
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Table I. Neurophysiological and neuropsychological endophenotypes: effect size difference between schizophrenia patients, normal comparison groups,
and schizophrenia spectrum groups. Effect sizes in schizophrenia patients, clinically unaffected relatives of schizophrenia patients, and schizo-
typal personality disordered patients compared with those in normal subjects. These effect sizes were computed by using the mean and stan-
dard deviations for normal comparison subjects and the means of the patient groups. The range of values differs from study to study because
different investigators used different patient populations taking different types and amounts of medications; also, multiple conditions were
used, some of which were needed to establish the floor and ceiling effect. In these cases, we generally cited the most robust effect sizes. *Also,
Cadenhead KS, unpublished data, 2000.
Endophenotypes Schizophrenia Relatives of  Schizotypal personality  References
patients schizophrenia patients disordered patients
Antisaccade 4.88-6.38 1.38-3.75 0.75-1.36 15, 16
Smooth-pursuit eye movement 2.0-3.0 0.29-1.3 0.29 16-18
Thought disorder 1.56-2.98 0.34-0.83 1.04-1.28 16, 19-21
Working memory  1.42-2.2 0.42 0.73-1.04 22-24
P50 suppression 0.92-1.29 0.79 0.79 25, 27
Reaction time 0.59-1.05 0.44 0.79-0.99 28-30
Prepulse inhibition 0.51-0.85 1.0 1.45 31-33
Span of apprehension  0.5-2.5 0.6-1.5 34-39
Continuous performance test 0.45-3.30 0.46-2.97 0.45-0.78 34, 40-42
Executive functioning 0.47-1.97 0.73-1.6 0.72 40, 43
P300 event-related potential 0.45-1.05 0.17 0.36 44,45
Visual backward masking 0.33-0.65 0.43-0.57 0.45-0.67 28, 46, 47*
Figure 2. The vulnerability-stress 2-hit model of schizophrenia. “High” lev-
els of vulnerability interacting with high levels of stressors (eg,
neonatal hypoxema or adolescent stimulant abuse) may “evoke”
the emergence of schizophrenia. Despite the view of schizo-
phrenia as a “genetic disorder,” 50% of causation is genetic and
50% or so of the disorder is caused by “nongenetic” second hits.
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No clinical sequelaeplexities into understanding the genetic architecture and
nongenetic contributions into quantitative measures that
are amenable to analysis via advanced statistical quanti-
tative trait analytic genetic methods.
11-14Thus,for a com-
plex psychiatric illness like schizophrenia,the relationship
between genes,gene products,and the disorder itself is
hardly straightforward.Indeed,an understanding of the
exact cascade of DNA to RNA to (abnormal) protein to
endophenotypic dysfunction in schizophrenia has
remained elusive, but is amenable to serious investiga-
tions and analyses.
Because of the complexity of schizophrenia and the fact
that it is a “fuzzy” diagnostic phenotype, a number of
strategies have been utilized in order to understand the
genetic underpinnings of the disorder.The most simple
and most commonly used strategy of molecular genetics
that is applied to complex psychiatric disorders first
assumes the distribution of illness in a family represents
the effect of a single gene and utilizes the techniques of
genetic analysis that are commonly used to identify that
single gene.This approach assumes that the signal of the
disease attributable to a single gene can be identified in
the very complex and relatively “noisy” genetic back-
ground of the disease.
As an alternative approach,one could make an assump-
tion about the biology or endophenotypes expressed in
an illness and then search for candidate genes that under-
lie those functions to see if they are mutated.It is impor-
tant to note that both of these approaches have been suc-
cessful to some degree in schizophrenia studies. For
example,whole genome scans have revealed replicated
linkage findings for schizophrenia obtained at locations
on chromosomes 1,6,8,13,15,and 22 (see,for example,
references 7 and 48). The problem with these whole
genome linkage studies is that the functional correlates of
these linkages are unclear.Conversely,DNA mutations
have also been found in “candidate genes” such as
NURRI,
50 a gene that codes for the receptor for retinoic
acid and mediates critical pathways in neuronal develop-
ment.A limiting consequence of dealing with a group of
disorders is that these neurobiologically significant and
face-valid abnormalities in NURRI candidate genes are
mutated in only a small number of patients with a diag-
nosis of schizophrenia.
51
A third approach uses endophenotypes to sharpen the
clinical phenotype, in order to understand the genetic
basis of specific schizophrenia-linked abnormalities.This
approach assumes that a specific genetic abnormality
causes a specific protein change leading to a specific quan-
titative functional abnormality.Thus, the wide array of
possible genetically mediated domains that could be
examined in schizophrenia include metabolic functions,
brain structure and functional imaging,neurophysiology,
neuropsychology,and other endophenotypic abnormali-
ties that run in families.
7,9,51The relationship between these
endophenotypic abnormalities and genes can also be dis-
covered and evaluated via the use of linkage or candidate
gene analysis. Hence, levels of association of specific
quantitative traits and their related genetic abnormalities
would be stronger than the relationship of specific genetic
abnormalities to the clinical endophenotype of a hetero-
geneous population of schizophrenia patients. This
approach is hardly unique since it is clear in other med-
ical conditions that the search for endophenotypes and
their genetic determinants can be more “focused”when
looking through an “endophenotypic lens” rather than
looking at the genetic basis of the complex disorders
themselves.For example,in hemochromatosis,it is not the
clinical illness,but rather a high serum level of iron that is
the most clearly identifiable and penetrant heritable
trait.
52 Likewise, gene discovery in colon cancer has
revealed that it is not the cancer itself,but rather famil-
ial polyposis that is the crucial,
53 genetically heritable dis-
ease vector.In the case of colon cancer,the assumption is
that there is a genetically mediated vulnerability resulting
in polyp formation,which converts to cancer via the influ-
ence of other genetic or nongenetic factors (ie,diet,envi-
ronmental toxin exposure).Thus,these polyps will often
convert to colon cancer in “high-risk”individuals.
The assessment of endophenotypes has come to be
increasingly important in our attempts to understand
schizophrenia.Of course,when one considers that there
are about 16 000 genes expressed in the brain and, of
these,about 6000 to 8000 are expressed only in the brain,
54
searching for causative genes associated with the clinical
entity of schizophrenia per se is a daunting task.In deal-
ing with quantitative endophenotypic markers and the
probability of causal genetic heterogeneity where multi-
ple mutations may induce endophenotypic abnormalities,
we face a difficult challenge.Also,in analyzing endophe-
notypic abnormalities, the fact that many brain-based
genes are expressed in multiple areas,under varying pro-
moting or disease-inducing nongenetic conditions and
across critical neurodevelopmental epochs in the life of
the individual, the search for endophenotype–genetic
“connections” requires us to sharpen our focus when
Basic research
128searching for the vulnerability gene(s) in schizophrenia.
According to Mendel’s second law that genetic traits seg-
regate independently in the family, some siblings will
express specific endophenotypes independently of others
and may be better subjects for characterizing endophe-
notypic abnormities than the patients themselves. The
patients themselves have multiple abnormalities relating
to the scope and severity of their disease,the treatments
used for the disease,and the psychosocial,medical,nutri-
tional,and many factors associated with schizophrenia.
The voyage that has been undertaken in searching for
endophenotypes in schizophrenia has taken advantage of
a generation of important scientific findings.First among
these,of course,is the fulcrum finding of the double helix
structure of DNA.
55 Second,after the structure of DNA
was identified,the advances in the understanding of the
transformation of DNA to RNA to proteins to function
have taken place over the last 50 years in a rapidly accel-
erated fashion that has enabled us to come within “hailing
distance”of truly understanding the relationship of DNA
mutations to clinical and endophenotypic abnormalities.
Genetic studies of endophenotypes 
in schizophrenia
The candidate endophenotypes that have been examined
in schizophrenia range from metabolic and developmen-
tal measures to brain structural and functional traits,as
well as neuropsychological and neurophysiological
indices.The neurodevelopmental endophenotype candi-
dates include mutations in candidate genes such as
NURRI.Clearly,this pathway is critical in neuronal devel-
opment and, although the mutations in this gene are
found in a minority of schizophrenia patients,one cannot
help but be impressed by the fact that this endopheno-
typic trait aligns with a neurodevelopmental hypothesis.
Likewise, Harrison and Weinberger
51 have pointed out
that “schizophrenia genes”and their expression may con-
verge on critical neuronal synaptic and glial populations
in crucial brain areas, such as the hippocampus, dorsal
thalamus,and dorsolateral prefrontal cortex.These struc-
tures are all part of the cortico-striato-pallido-thalamic
(CSPT) circuitry.This CSPT circuitry involves complex
loops and connections that are derived from Penney and
Young’s
56 examination of the neural substrate of motor
functions. The finding of distributed neural network
abnormalities in the CSPT circuitry was described in psy-
chiatric populations in a definitive manner by Swerdlow
and Koob
57 and has led to many neurophysiological and
“brain connectivity” hypotheses. These hypotheses
include Andreason’s concept of cognitive dysmetria,
58
which attempts to “connect the dots”of brain dysfunction
in schizophrenia patients,
59 and the evolution of cortico-
cortical coherence measures to assess functional connec-
tivity deficits to probe the multiple cognitive deficits of
schizophrenia patients.
60 As Harrison and Weinberger
point out,“a way forward is provided by the recent iden-
tification of several putative susceptibility genes includ-
ing neuroregulin, dysdindin, COMT, DISCI, RGS4,
GRN3, G72.”
51 These authors discuss the evidence for
these and other genes as vulnerability vectors along
dimensions of their expression profiles and neurobiolog-
ical roles.While the evidence for genetic abnormalities in
these critical genes with their important integrative func-
tions is attractive,the causative allele or mechanism that
results in the development of schizophrenia is unknown.
Harrison and Weinberger
51 also point out that COMT
may be an exception where a causative allele may have
been identified. Nevertheless, in the area of brain con-
nectivity and synaptic plasticity,they have proposed that
the genes cited above may all converge functionally via
an influence upon synaptic plasticity and the development
and stabilization of functionally important cortical micro-
circuitry.
51 Thus, at the most basic level, these neurode-
velopmental genes may characterize a molecular biolog-
ical basis for a genetic cytoarchitecture that has the
potential to incrementally advance our understanding of
schizophrenia.
Neurophysiological endophenotypes: 
gating abnormalities
Many neurophysiological endophenotypes have under-
gone extensive study and analysis (Table I).
15-47 These
endophenotypic measures include antisaccade oculomo-
tor functioning,smooth pursuit eye movement,P50 sup-
pression,prepulse inhibition (PPI) of the startle response,
P300 ERPs,and visual backward masking.Each of these
endophenotypes has undergone a logical,natural history
of progression in scientific analyses: schizophrenia
patients,their clinically unaffected family members,and
schizotypal personality disordered subjects have deficits
compared with normal subjects. Exemplars of neuro-
physiological endophenotypes in schizophrenia are the
gating abnormalities reflected by PPI and P50 suppres-
sion deficits.
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129Abnormalities of sensorimotor (PPI) and sensory (P50
suppression) gating are thought to reflect an inability to
screen out trivial stimuli in order to focus on important
and information laden aspects of the environment.
61-64
Normal sensory gating (Figure 3) allows individuals to
navigate through a stimulus-laden world and to apportion
attentional resources to salient stimuli.PPI of the startle
reflex measures sensorimotor gating with a clear under-
standing of the underlying CSPT circuitry defined from
decades of animal model studies.While PPI and P50 sup-
pression measures of “gating” are often conceptually
linked, there is evidence that they actually diverge in
nonpsychiatric and clinical populations.
65-68Thus,these two
different,but seemingly closely related gating abnormal-
ities, may be characteristic of different subgroups of
patients.
PPI normally occurs when a weak prestimulus precedes
a strong “startling”stimulus by 50 to 300 ms (Figure 4);
the weak prestimulus inhibits the startle response. PPI
deficits in schizophrenia patients
31,61,69 extend to clinically
unaffected relatives of schizophrenia patients as well as
schizotypal patients.
33,70 Impaired gating function puta-
tively results in the devastating consequences of cognitive
fragmentation (Figure 3).
One of the major advantages of endophenotypes,such as
PPI,is that there are animal models that point to geneti-
cally mediated strain-related differences
71 and to specific
quantitative trait loci (Schork et al, 1995, unpublished
manuscript).In addition to strain-related differences in
baseline PPI,pharmacological regulation of PPI is also
strain-related.
71-77 In addition,PPI deficits induced by the
dopamine agonist apomorphine are reversed in a very
lawful manner by antipsychotic medications with
“dose–response”characteristics that parallel the efficacy
of these antipsychotic medications in schizophrenia
patients.
78Therefore,although PPI is not as advanced in
terms of its genetic analysis as P50 suppression (see
below),it offers an important window on endophenotype
(dys)function in schizophrenia.The CSPT circuitry is cru-
cial for understanding cognitive integration and inhibitory
functions. In animal model studies, this circuitry is
impaired by lesions or neurotransmitter manipulations at
multiple loci in the CSPT circuitry that induce PPI
deficits.
79,80Thus,infusion and lesion studies along nodes
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Figure 3. The effects of a loss of normal gating. In the left panel, an individual with intact filtering and inhibition filters out irrelevant sensory stimuli.
In the right panel, impaired gating leads to a sequence of sensory inundation, cognitive fragmentation, and disorganized thinking.
Sensory and sensorimotor gating in normal and schizophrenia subjects:
the effects of impaired gating
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within the CSPT axes can disrupt PPI.It is not too big a
“leap of faith”to believe that specific single nucleotide
polymorphisms (SNPs) might affect these loci and reflect
multiple genetic mutations that contribute to the vulner-
ability to developing schizophrenia. Of course, these
hypotheses can only be worked out in humans in large-
scale studies such as the National Institute of Mental
Health Consortium of Genetics of Schizophrenia,
81 where
endophenotype deficits found in schizophrenia are being
tracked in a large cohort of families in order to under-
stand both patterns of heritability and the specific genetic
abnormalities associated with these endophenotypic
deficits in schizophrenia.
P50 suppression is an ERP measure of inhibitory function
that has been studied in a variety of patient and nonpsy-
chiatric populations.An electroencephalogram (EEG) is
recorded in response to click pairs presented 500 ms apart.
The EEG responses to each of the clicks are separately
averaged.The P50 component of the auditory ERP is a
positive-polarity waveform that occurs approximately 50
ms after each click is presented.In normal subjects,the P50
response to the second click is typically reduced in ampli-
tude relative to the response to the first click.
25,26,82-84 P50
suppression is the percentage of P50 response amplitude
reduction from the first to the second click (Figure 5).
Over the past 20 years,many studies have demonstrated
that schizophrenia patients have P50 suppression deficits
(Table I) and that these deficits extend to clinically unaf-
fected relatives of schizophrenia patients.
26,85-87 Individuals
with schizotypal personality disorder also have P50 sup-
pression deficits,
27,88 indicating that these deficits are pre-
sent across the schizophrenia spectrum.
Although it is clear that,much like PPI,P50 suppression is
almost inevitably the function of a wide-ranging neural cir-
cuitry involving multiple brain structures and complex
brain circuits,the utilization of P50 suppression as a “can-
didate endophenotype”advanced rapidly for two reasons.
First,there was the critical findings of nicotine transiently
improving P50 suppression deficits in both schizophrenia
patients
89 and their clinically unaffected family members.
90
Second,an animal model of P50 suppression was devel-
oped,similar to that seen in PPI.This allows specific neu-
rochemical manipulations to be made and it was found
that P50 suppression deficits in DBA/2 mice could be
restored to normal levels by α7-agonists.
91Then,a relatively
unique element in the ideal progression of identifying
endophenotypes in schizophrenia was made:it was found
that there is a genetic marker at the locus of the α7-sub-
unit of the nicotinic receptor gene linking a candidate
endophenotype of information-processing deficits in schiz-
ophrenia to a specific chromosomal region.
84 Leonard et
Figure 4. Prepulse inhibition (PPI) is a profound decrease in startle response
magnitude when the startling pulse is preceded by a weak pre-
pulse. PPI is an operational measure of sensorimotor gating.
The basic PPI of the startle response paradigm
Inhibited
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startle
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Prepulse
50-300 ms
Stimuli Startle responses
Figure 5. Auditory click pairs are presented to subjects; the electro-
encephalogram (EEG) is averaged across trials. The P50 compo-
nent of the averaged event-related potential (ERP) is measured
in response to the first and second clicks. The percentage of P50
amplitude reduction from the first to the second click is referred
to as P50 suppression or P50 gating, and is considered an oper-
ational measure of sensory gating. Deficient P50 suppression
is often seen in patients with schizophrenia, their clinically unaf-
fected family members, and individuals with schizotypal per-
sonality disorder. 
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92 found a specific SNP genetic mutation in the promoter
region of the α7-subunit of the nicotinic gene,which seems
to account for the P50 findings listed above.Thus,P50 sup-
pression represents the most “complete”“DNA to RNA
to protein” story of an endophenotype–genetic abnor-
mality linkage.
The P50 suppression findings represent an example of
how endophenotypes can be utilized as neurobiologically
meaningful markers that contribute to our understanding
of the genetics and potentially the treatment of schizo-
phrenia.Importantly,these types of studies do not merely
identify a “schizophrenia endophenotype,”but rather the
linkage of deficits (P50 suppression) in schizophrenia
patients to a specific chromosomal region.
Conundrums and caveats, and the use 
of endophenotypes in the genetics 
of schizophrenia
Although there are many candidate endophenotypes in
schizophrenia,imposing challenges still exist.First,since
some endophenotypes are at least partially normalized by
current second-generation antipsychotic medications,the
statistical genetic approach to these data sets presents
many daunting challenges. For example, the fact that
clozapine improves P50 suppression deficits
93-95 suggests
that patients on clozapine cannot be utilized in studies of
P50 suppression as a candidate endophenotype.It would
be optimal to use never-medicated schizophrenia patients
in studies of endophenotypes in schizophrenia.
Unfortunately,given the power demands of such studies,
finding enough never-medicated patients,even in a multi-
site study such as the Consortium on the Genetics of
Schizophrenia (COGS) would seem to be virtually impos-
sible.Family studies that rely on identifying probands with
endophenotypic deficits then become difficult to inter-
pret.Where significant endophenotypic normalization
occurs with antipsychotic treatment,statistical strategies
will have to be utilized that allow us to “exclude” or
“account for”the (partially) “normalized”schizophrenia
patients or to utilize only clinically unaffected family
members in genetic studies. This reliance on clinically
unaffected family members is what Braff and Freedman
7
referred to as the “null-proband” strategy. Medicated
probands must either be excluded from analyses or a
complex “adjustment” on a phenotypic value must be
made in order to utilize them in the genetic analysis.One
could posit that a temporary withdrawal of antipsychotic
medication would allow us to identify these trait-related
endophenotypic markers,but this is ethically and practi-
cally unfeasible.Fortunately,almost all of the large effect
sizes reported for endophenotypic deficits in schizophre-
nia in Table I are derived from medicated patients,so that
it appears that fairly straightforward statistical analyses
can be utilized with most available patients.
Summary
Genetic studies in schizophrenia are on the cusp of an
exciting new era of utilizing specific laboratory-based
endophenotypes to parse the complex genetic architecture
of the “groups of schizophrenia.”The template described
above for P50 suppression studies has already yielded a
sequence of findings leading to the identification of a spe-
cific abnormality that accounts for P50 suppression deficits
in schizophrenia patients and their clinically unaffected
relatives.In addition to this,there are many studies exam-
ining heritability of other strong candidate endopheno-
types,as listed in Table I.Other study strategies are now
being utilized in endophenotypic research in schizophre-
nia.Investigations are underway in a number of settings
to identify genes that convey a risk for schizophrenia.For
example,whole genome linkage studies have revealed loci
that might be of functional importance.In addition,the
endophenotypic strategy,however,allows us to understand
the underlying neurobiology and neural substrates of these
genetic abnormalities.Many conundrums and obstacles
must be overcome in this endeavor. For example, the
improvement of endophenotypic abnormalities via the use
of second-generation
96 antipsychotic medications may (or
may not) impede our ability to carefully conduct family
heritability studies,which will allow us to ultimately iden-
tify genetic abnormalities characteristic of schizophrenia.
With the use of statistical genetics methods,unmedicated
patients,animal model identification of quantitative trait
loci,and specific genetic abnormalities,the exciting possi-
bility exists for matching endophenotypes with their
underlying genetic abnormalities and then constructing
“composite endophenotypes”consisting of neurobiologi-
cally coherent combinations of more than one of the iden-
tified biomarkers.It is very important to identify the con-
vergence and divergence of these endophenotype–gene
abnormality linkages in schizophrenia patients in order to
see whether a single genetic abnormality is likely to induce
the multiple observed deficits of schizophrenia patients.
Ultimately,the specification of how different gene–envi-
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132ronment interactions contribute to neuronal pathology
associated with psychosis may enable us to further clar-
ify the nosology of schizophrenia.Quantitative endophe-
notype-based strategies play an important role that will
help elucidate the genetic basis of schizophrenia and point
the way toward molecularly derived strategies for the
treatment of important subgroups of patients with this
complex disorder. ❏
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El empleo de endofenotipos 
neurofisiológicos para comprender las 
bases genéticas de la esquizofrenia
El poder precisar la compleja arquitectura genética
del “enredado” fenotipo clínico de la esquizofrenia
constituye un problema gigantesco. El empleo de
mediciones endofenotípicas metabólicas, neuro-
cognitivas y neurofisiológicas “intermediarias”
ofrece ventajas significativas desde un punto de
vista genético estadístico. Las mediciones endofe-
notípicas sustituyen a los análisis genéticos cuanti-
tativos confiriéndoles a ellas una mayor ventaja
metodológica en comparación con los diagnósticos
principalmente cualitativos que emplea el Manual
Diagnóstico y Estadístico de Salud Mental en su
cuarta edición (DSM IV). Los déficits endofenotípi-
cos aparecen en todo el espectro esquizofrénico: en
pacientes con esquizofrenia, en pacientes esquizo-
típicos y en familiares de pacientes esquizofrénicos
sin evidencias clínicas de la enfermedad. Las medi-
ciones neurofisiológicas, como la supresión de los
eventos relacionados con la onda P50 y la inhibición
de la respuesta de sobresalto ante un estímulo,
constituyen endofenotipos que pueden ser con-
ceptualizados como una alteración debida a una
anormalidad genética simple en la cascada funcio-
nal desde el ADN al ARN y a las proteínas. La “apro-
ximación endofenotípica” también se está emple-
ando para comprender otros cuadros médicos,
como el cáncer de colon, la hemocromatosis y la
hipertensión en los cuales hay una interacción entre
los estresores no genéticos y la predisposición gené-
tica que confiere cierta vulnerabilidad. En este artí-
culo se discutirá en detalle la capacidad y la utilidad
del empleo de endofenotipos para una mejor com-
prensión de la genética de la esquizofrenia.
Utilisation des endophénotypes 
neurophysiologiques pour comprendre 
la base génétique de la schizophrénie
Préciser l’architecture génétique complexe du phé-
notype clinique « enchevêtré » de la schizophrénie
constitue un problème impressionnant. Utiliser des
mesures endophénotypiques métaboliques, neuro-
cognitives et neurophysiologiques « intermé-
diaires » offre des avantages certains d’un point de
vue génétique statistique. Les mesures endophé-
notypiques relèvent des analyses génétiques quan-
titatives, leur conférant un avantage méthodolo-
gique majeur comparé aux diagnostics en grande
partie qualitatifs qui utilisent le DSM-IV (Diagnostic
and Statistical Manual of Mental Health, 4e édi-
tion). Des déficits endophénotypiques se produisent
au cours de la schizophrénie chez les patients schi-
zophrènes, les patients schizotypiques et les parents
cliniquement indemnes de patients schizophrènes.
Les endophénotypes sont des moyens neurophy-
siologiques, tels que la suppression des événements
liés au P50 et que l’inhibition de la réponse de sur-
saut avant un stimulus, que l’on peut imaginer être
altérés par une anomalie génétique simple dans la
cascade de fonctionnement ADN vers ARN vers pro-
téine. L’ « approche endophénotypique » est aussi
utilisée pour comprendre d’autres pathologies,
comme le cancer du colon, l’hémochromatose et
l’hypertension dans lesquels il existe une interaction
entre des agents stressants non génétiques et une
prédisposition génétique conférant une certaine
vulnérabilité. Dans cet article, nous allons parler en
détail de la possibilité et de l’utilité d’utiliser des
endophénotypes pour comprendre la génétique de
la schizophrénie.Basic research
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